Skip to main content

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. Securities may not be offered or sold in the United States of America (“US”) absent registration under the US Securities Act of 1933, as amended, or an exemption from registration. The securities described on the following pages are not offered for sale in the US or to "US persons" (as defined in Regulation S under the US Securities Act of 1933, as amended).

THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE US, CANADA, JAPAN OR AUSTRALIA OR WHO ARE US PERSONS (AS DEFINED IN REGULATION S UNDER THE US SECURITIES ACT OF 1933, AS AMENDED), OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that
(i) you are not a resident of the United States of America, Canada, Japan or Australia or a "US person" (as defined in Regulation S under the US Securities Act of 1933, as amended),
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

 

By clicking on the "Accept" button below, you will be deemed to have made this confirmation

 

 

Bonds

Issuer Volume in millionCouponMaturity

Fresenius SE & Co. KGaA

 €750 1.875% 2025

Fresenius SE & Co. KGaA

 €500 0.375% 2026

Fresenius SE & Co. KGaA

 €500 4.25% 2026

Fresenius SE & Co. KGaA

 €750 1.625% 2027

Fresenius SE & Co. KGaA

 €750 0.75% 2028

Fresenius SE & Co. KGaA

CHF275 2.96% 2028

Fresenius SE & Co. KGaA

 €500 2.875% 2029

Fresenius SE & Co. KGaA

CHF225 1.5975% 2029

Fresenius SE & Co. KGaA

 €500 5.00% 2029

Fresenius SE & Co. KGaA

 €550 2.875% 2030

Fresenius SE & Co. KGaA

 €500 5.125% 2030

Fresenius SE & Co. KGaA

 €500 5.125% 2030

Fresenius Finance Ireland plc.

 €500 0.00% 2025

Fresenius Finance Ireland plc.

 €700 2.125% 2027

Fresenius Finance Ireland plc.

 €500 0.50% 2028

Fresenius Finance Ireland plc.

 €500 0.875% 2031

Fresenius Finance Ireland plc.

 €500 3.00% 2032

Schuldschein loans

Issuer Volume in millionCouponMaturity

Fresenius SE & Co. KGaA

 €309 variable 2026

Fresenius SE & Co. KGaA

 €238 variable 2026

Fresenius SE & Co. KGaA

 €207 variable 2027

Fresenius SE & Co. KGaA

 €405 variable 2028

Fresenius SE & Co. KGaA

 €84 1.10% 2029

Fresenius SE & Co. KGaA

 €136 variable 2030

EIB loan

Issuer Volume in millionCouponMaturity

Fresenius SE & Co. KGaA

 €400 variable 2025

The European Investment Bank (EIB) is the biggest multilateral financial institution in the world and one of the largest providers of finance for climate action, providing economic support to sectors that contribute significantly to technological innovation,  growth, employment, regional cohesion and environmental sustainability in Europe and beyond. The EIB loan was provided to Fresenius in 2021 based on the expenditures in Research, Development and Innovation (RDI) in its portfolio of biosimilars, generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. The RDI activities in scope focus on developing lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

The information and documents contained on the following pages of this website are for information purposes only. These materials do neither constitute an offer nor an invitation to subscribe to or to purchase securities, nor any investment advice or service, and are not meant to serve as a basis for any kind of obligation, contractual or otherwise. The securities described on the following pages have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States of America (the "United States") absent registration or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offering of such securities in the United States or anywhere else and, if offered, any such securities will be offered and sold only (i) outside of the United States in "offshore transactions" in accordance with Regulation S of the Securities Act and (ii) in the United States to "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) in transactions exempt from the registration requirements of the Securities Act.


THE FOLLOWING INFORMATION AND DOCUMENTS ARE NOT DIRECTED AT AND ARE NOT INTENDED FOR USE BY (I) PERSONS WHO ARE RESIDENTS OF OR LOCATED IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA, OR (II) PERSONS IN ANY OTHER JURISDICTION WHERE THE COMMUNICATION OR RECEIPT OF SUCH INFORMATION IS RESTRICTED IN SUCH A WAY THAT PROVIDES THAT SUCH PERSONS SHALL NOT RECEIVE IT. SUCH PERSONS, OR PERSONS ACTING FOR THE BENEFIT OF ANY SUCH PERSONS, ARE NOT PERMITTED TO VISIT THE FOLLOWING PAGES OF THE WEBSITE.

To visit the following parts of this website you must confirm that
(i) you are not a resident of or located in the United States, Canada, Australia, Japan or South Africa,
(ii) you are not a person to whom the communication of the information contained on the website is restricted,
(iii) you will not distribute any of the information and documents contained thereon to any such person, and
(iv) you are not acting for the benefit of any such person.

By clicking on the "Accept" button below, you will be deemed to have made this confirmation.

 

The Fresenius SE & Co. KGaA Commercial Paper Program enables Fresenius to issue short-term notes of up to €1.5 bn on the money market. The issuances are made through the European Commercial Paper Program (ECP). 

 
Issuer: 

Fresenius SE & Co. KGaA, Fresenius Finance Ireland plc.

Program amount € 1,500,000,000
Arranger

Commerzbank

Dealer

Barclays, Commerzbank, Crédit Agricole, DZ BANK AG, Landesbank Baden-Württemberg, Landesbank Hessen-Thüringen, ING Bank N.V.

Issuing and paying agent Commerzbank
Term up to 1 year less 1 day